 The FDA has approved Takeda Pharmaceutical Co Ltds TAK Vonvendi von Willebrand factor Recombinant for routine prophylaxis to reduce the frequency of bleeding episodes in Type 3 von Willebrand disease VWD receiving on-demand therapy. ALERT Nic Chahine shares his Bear Market Beating options trading strategy. 